SCHEMBL13629310

SCHEMBL13629310

O=c1c2ccccc2cnc2ncccc12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.43
PARP1 P09874 3/20 0.43
HSD17B10 Q99714 2/20 0.43
PRKCI P41743 1/20 0.43
PDE4B Q07343 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
KDM4E B2RXH2 3/20 0.42
GPR3 P46089 1/20 0.42
LMNA P02545 1/20 0.42
CYP3A4 P08684 1/20 0.40
IDO1 P14902 2/20 0.39
HCAR2 Q8TDS4 2/20 0.38
F2 P00734 1/20 0.38
F10 P00742 1/20 0.38
F7 P08709 1/20 0.38
F3 P13726 1/20 0.38
GAA P10253 1/20 0.37
MAPT P10636 1/20 0.37
HPGD P15428 1/20 0.37
AXL P30530 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13629307 0.84 IDO1 (0.43) ALDH1A1PARP1KDM4ELMNAIDO1
SCHEMBL2406867 0.84 KDM4E (0.54) ALDH1A1PARP1HSD17B10PRKCIPDE4B
SCHEMBL30598019 0.84 KDM4E (0.54) ALDH1A1PARP1HSD17B10PRKCIPDE4B
Water SCHEMBL8370901 0.82 KDM4E (0.52) ALDH1A1PARP1HSD17B10PRKCIPDE4B
SCHEMBL31318624 0.82 KDM4E (0.52) ALDH1A1PARP1HSD17B10PRKCIPDE4B
SCHEMBL28661854 0.82 KDM4E (0.52) ALDH1A1PARP1HSD17B10PRKCIPDE4B
SCHEMBL29077538 0.82 KDM4E (0.52) ALDH1A1PARP1HSD17B10PRKCIPDE4B
SCHEMBL13629318 0.79 KDM4E (0.45) ALDH1A1PARP1KDM4ELMNACYP3A4
SCHEMBL13166553 0.75 LMNA (0.37) ALDH1A1PARP1HSD17B10KDM4ELMNA
SCHEMBL11466448 0.75 KDM4E (0.69) ALDH1A1PARP1HSD17B10PRKCIPDE4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090291941-A1 Tyrosine Kinase Inhibitors MERCK SHARP & DOHME CORP. 2009-11-26 US disclosed
US-20090291941-A1 Tyrosine Kinase Inhibitors MERCK SHARP & DOHME CORP. 2009-11-26 US disclosed
US-20090131423-A1 Tyrosine Kinase Inhibitors MERCK & CO., INC. (US) 2009-05-21 US disclosed
WO-2007050383-A2 TYROSINE KINASE INHIBITORS MERCK & CO., INC. (US) 2007-05-03 WO disclosed
WO-2007050401-A2 TYROSINE KINASE INHIBITORS MERCK & CO., INC. (US) 2007-05-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090291941-A1 Tyrosine Kinase Inhibitors ABL1, ERBB2, RET ALDH1A1 1303/4885PARP1 1817/4885HSD17B10 3346/4885
US-20090131423-A1 Tyrosine Kinase Inhibitors ABL1, ERBB2, MET ALDH1A1 1458/4885PARP1 2302/4885HSD17B10 4440/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.